Short-sellers bet syringe maker Unilife will plunge

US-based short-sellers are betting that the share price of ASX-listed biotech firm Unilife is going to zero – and also see surf-wear company Quicksilver heading for a wipeout.

Jonathan ShapiroSenior reporter

Updated May 11, 2014 – 12.15pm, first published at May 9, 2014 – 9.47am

Email LinkedIn Twitter Facebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

US-based short-sellers are betting that the share price of ASX-listed biotech firm Unilife is going to zero.

The controversial collapsible syringe maker that is dual-listed on the ASX and US NASDAQ exchange has fought back from mounting scepticism from bloggers and short sellers about its worth.

Jonathan Shapiro writes about banking and finance, specialising in hedge funds, corporate debt, private equity and investment banking. He is based in Sydney.